AI tailors insulin dosing
New AI platforms are now combining CGM streams, dietary logs and activity trackers to tailor insulin‑dosing guidance in real time—aiming to cut hypoglycaemia and improve long‑term control, according to a March 29 media roundup. Clinics are already embedding these AI dashboards into EHR workflows, and panelists report algorithms can forecast blood‑sugar crashes hours ahead to give patients an intervention window. (diabetesdaily.com) (vocal.media)
DreaMed’s commercial platform (branded endo.digital / Advisor Pro) is an FDA‑cleared clinical decision‑support tool that ingests CGM streams, insulin dosing logs and meal entries and generates recommendations for basal rates, carbohydrate‑to‑insulin ratios and correction factors. (accessdata.fda.gov) (dreamed.ai) Yale New Haven Health integrated DreaMed’s decision‑support output directly into patient electronic medical records in January 2023 so clinicians can launch the dashboard from the chart. (businesswire.com) DreaMed’s Advisor Pro was tested in ADVICE4U, a multinational six‑month randomized trial of 108 youths using insulin pumps that found AI‑guided dose optimization was noninferior to endocrinologist guidance (time in range 50.2% vs 51.6%). (nature.com) A more recent multisite randomized inpatient study reported similar noninferiority for an AI insulin clinical decision support system during five‑day hospital admissions, with time‑in‑range of 76.4% for the AI group versus 73.6% for physician‑managed care. (jamanetwork.com) Validation work on glucose forecasting shows prediction horizons vary by model: ensemble and deep‑learning systems have demonstrated accurate hypoglycemia forecasts at 30–60 minutes (with reported sensitivities >97% in some datasets) and other studies report reliable forecasts out to 120 minutes; separate models have been developed to estimate week‑ahead hypoglycemia risk for population‑level prioritization. (sciencedirect.com) (nature.com) (journals.sagepub.com) Vendors advertise turnkey EHR/EMR connections using FHIR and third‑party diabetes‑device integration, and clinician surveys tied to the Advisor Pro trial reported high usability and uptake (96% of endocrinologists rated the tool intuitive, 86% said it saved time and physicians accepted Advisor recommendations in ~98% of cases). (dreamed.ai)
